Humacyte Stock Earnings Reports

Humacyte reported Q1 2026 commercial sales of Symvess of $0.5M (29 units), up from $0.1M in Q1 2025, but management said adoption must accelerate. The company has reorganized its commercial organization, hiring a new Chief Commercial Officer (James Mercadante) and Chief Surgical Officer (Dr. Todd Rasmussen) to improve surgeon education and drive uptake, and reduced headcount by ~25% (45 employees) to cut costs. Restructuring will incur ~ $0.8M in one-time severance charges and is expected to yield roughly $14.3M in net savings for the remainder of 2026. Clinical development milestones: top-line interim results from the V012 Phase III dialysis access trial (women-only) are expected to be presented around June 11, 2026 at the Vascular Annual Meeting; subject to positive results, Humacyte plans to submit a supplemental BLA for dialysis in H2 2026. The company also plans to initiate a first-in-human Phase I/II study of its coronary tissue engineered vessel (CTEV) in CABG in H2 2026 pending manufacturing completion and FDA clearance. International expansion is underway (MAA accepted for review in Israel; $1.475M purchase commitment from Saudi Arabia; regained ex-U.S. rights from Fresenius opening ex-U.S. partnerships). The U.S. Department of Defense has allocated funding to evaluate biologic vascular repair technologies, which could support military adoption. Financials: Q1 net loss was $17.6M versus net income of $39.1M in Q1 2025; cost of goods rose to $2.0M (including a $1.6M inventory reserve and overhead for unused capacity); R&D increased to $19.5M driven by CTEV manufacturing and process improvements. Cash, cash equivalents and restricted cash were $48.9M as of March 31, 2026. Management did not provide full-year revenue guidance and said they hope to provide guidance by year-end.